Search
Gestrinone
go.drugbank.com/drugs/DB11619ApprovedGestrinone, also known as ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group that is marketed in Europe, Australia, and Latin America, though not the United States or Canada, and
Capmatinib
go.drugbank.com/drugs/DB11791ApprovedInvestigational[L13347] The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same … [L13347] Capmatinib was approved by Health Canada on June 8, 2022.[L42015]
Siponimod
go.drugbank.com/drugs/DB12371ApprovedInvestigationalSymptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. … It was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020.
Phylloquinone
go.drugbank.com/drugs/DB01022ApprovedInvestigational[L33319] Phylloquinone has been synthesized since at least 1939,[A234384] and was approved by the FDA prior to 1955.[L33389] … [A234264,A234195,A234259] It is indicated in the treatment of coagulation disorders due to faulty formation of coagulation factors II, VII, IX, and X caused by deficiency or interference in the activity
Products: Vitamin K1 Inj 10mg/ml, KISAN INJECTION 10MG/MLGatifloxacin
go.drugbank.com/drugs/DB01044ApprovedInvestigationalWithdrawnIt works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. … It is also available as eye drops under the brand name Zymar® marketed by Allergan.
Sevabertinib
go.drugbank.com/drugs/DB21667ApprovedInvestigational[L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608]
Bezlotoxumab
go.drugbank.com/drugs/DB13140Approved[A260106] The drug was granted full approval by the EMA on January 18, 2017.[L47191] … [L46976] First approved by the FDA on October 21, 2016,[A260106] bezlotoxumab is used to reduce the recurrence of _C. difficile_ infection.
Bucetin
go.drugbank.com/drugs/DB13278ApprovedWithdrawnBucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn from the market in 1986 due to renal toxicity caused by the medication.[A175636]
Capreomycin
go.drugbank.com/drugs/DB00314ApprovedInvestigationalIt is produced by Streptomyces capreolus.
Sipuleucel-T
go.drugbank.com/drugs/DB06688ApprovedInvestigationalThe treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014. … In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). Sipuleucel-T is marketed under the brand name Provenge by Dendreon Corporation.